Navigation Links
Inverness Medical Innovations Announces Second Quarter 2008 Results
Date:7/29/2008

s $45.2 million of costs associated with stock option

acceleration and conversion in connection with our acquisition of Biosite,

Inc.

(e) A write-off in the amount of $0.3 million and $1.2 million during the

second quarter of 2008 and 2007, respectively, relating to inventory

write-ups recorded in connection with the acquisitions of Panbio Limited

and BBI Holdings Plc. during the first quarter of 2008 and Biosite, Inc

during the second quarter of 2007.

(f) A charge of $15.4 million associated with the write-off of debt

origination costs and a prepayment premium paid upon early extinguishment

of related debt during the 2007 quarter, in conjunction with our financing

arrangements related to our Biosite acquisition.

(g) A $1.9 million foreign currency gain realized on the settlement of

intercompany notes during the 2007 quarter.

(h) Tax effect on adjustments as discussed above in notes (b), (c), (d),

(e), (f) and (g).

(i) For the three months ended June 30, 2008 and 2007, potential dilutive

shares were not used in the calculation of diluted net loss per common

share under GAAP because inclusion thereof would be antidilutive.

(j) Included in the weighted average diluted common shares for the

calculation of net income per common share for the three months ended June

30, 2008, on an adjusted cash basis, are dilutive shares consisting of

1,926,000 common stock equivalent shares from the potential exercise of

stock options and warrants and potential dilutive shares consisting of

3,411,000 common stock equivalent shares from the potential conversion of

convertible debt securities. The net income per diluted share calculation

for the three months ended June 30, 2008, on an adjusted cash basis,

includes the add back of interest expense related to the convertible debt

of $0.8 million resulting in net income
'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Inverness - Chemogen Establish Exclusive License for TB Antibodies
3. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
4. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
7. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
8. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
9. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
10. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
11. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... The third Medical Innovation Impact Index (MI3) Alert ... particular, drug/device combinations. The current system received a score of 0 (range -10 to ... Innovation (iPCI) of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... introduces CHRONO NIGHT Express Contouring Bi-Gel, a nighttime-specific product that targets fat ... of sugars that are able to enter fat cells, inhibiting the formation of ...
(Date:7/28/2015)... LONDON , July 29, 2015 ... on acquiring, rapidly developing and commercialising ... human health   Highly experienced management team; ...     Mereo BioPharma Group Ltd ... successfully raised $119m ( c. £76.5m), gross, from blue ...
(Date:7/28/2015)... 28, 2015 Seahorse Bioscience, the industry ... the provider of XF Technology which is increasingly ... areas. As the links between mitochondrial function and ... is escalating rapidly.   Recently, 12 ... Publishing Group (NPG) featuring XF Technology, including Nature, ...
Breaking Biology Technology:Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3
... In order,to meet its obligations under the Listing Rules ... NASDAQ: SHPGY, TSX: SHQ) is,publishing today its interim results ... with International Financial Reporting Standards (IFRS). It should ... its results in,respect of the same period in accordance ...
... ... Shears, ... company, has been named a 2007 Innovator of the,Year by the ... newest Tissue Ligating Shears, the TLS3,which uses the Company,s innovative seal ...
... in development targeting glucagon ... research collaboration to identify antisense drugs to inhibit ... - Conference call webcast Thursday, September 13, 9:45 a.m. EDT at ... http://www.isispharm.com , CARLSBAD, Calif., Sept. 13 ...
Cached Biology Technology:IFRS Information - First Half of 2007 2IFRS Information - First Half of 2007 3IFRS Information - First Half of 2007 4IFRS Information - First Half of 2007 5IFRS Information - First Half of 2007 6IFRS Information - First Half of 2007 7IFRS Information - First Half of 2007 8IFRS Information - First Half of 2007 9IFRS Information - First Half of 2007 10IFRS Information - First Half of 2007 11IFRS Information - First Half of 2007 12IFRS Information - First Half of 2007 13IFRS Information - First Half of 2007 14IFRS Information - First Half of 2007 15IFRS Information - First Half of 2007 16IFRS Information - First Half of 2007 17IFRS Information - First Half of 2007 18IFRS Information - First Half of 2007 19IFRS Information - First Half of 2007 20IFRS Information - First Half of 2007 21IFRS Information - First Half of 2007 22IFRS Information - First Half of 2007 23IFRS Information - First Half of 2007 24IFRS Information - First Half of 2007 25IFRS Information - First Half of 2007 26IFRS Information - First Half of 2007 27IFRS Information - First Half of 2007 28IFRS Information - First Half of 2007 29IFRS Information - First Half of 2007 30IFRS Information - First Half of 2007 31IFRS Information - First Half of 2007 32IFRS Information - First Half of 2007 33Society of Laproendoscopic Surgeons Names Starion Instruments 2007 Innovator of the Year 2Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 2Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases 3
(Date:7/20/2015)... -- Acuity Market Intelligence,s latest research "The Global Biometrics ... Privacy" forecasts that between 2014 and 2020 nearly ... to smart mobile devices by 2.2 billion mobile ... to generate more than $67.9 billion in total ...    "Biometrics is at the center ...
(Date:7/9/2015)... 07, 2015 Research ... of the "Biometrics for Banking; Market & ... report to their offering. The adoption ... this growth and the forecast is that by ... for companies involved in delivering biometric systems to ...
(Date:7/8/2015)... YORK , July 8, 2015  BD (Becton, ... BD & Guidepoint Mentor, a new program ... Guidepoint,s expert network services. BD is ... to improve healthcare delivery and outcomes and, with the ... entrepreneur will be able to directly engage with industry ...
Breaking Biology News(10 mins):Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... for our buildings, bridges, dams, and roads. We walk on ... its walls. Yet very few of us know what it ... this familiar landscape for granted; yet the story of its ... remarkable historical episodes. A new history of concrete, "Concrete Planet: ...
... drinking water when they are thirsty; but by then it ... alter a person,s mood, energy level, and ability to think ... of Connecticut,s Human Performance Laboratory. The tests showed that ... 40 minutes on a treadmill or was sitting at rest ...
... , ,It,s not a take on climate change we ... University Canada Research Chair and professor of archaeology, will ... the world,s largest science fair., The 2012 American Association ... 16 to 20 at the Vancouver Convention Centre in ...
Cached Biology News:Hidden in plain sight, concrete holds a strange history 2Cranky today? Even mild dehydration can alter our moods 2Cranky today? Even mild dehydration can alter our moods 3AAAS-SFU research: Linking human evolution and climate change 2
...
EPA II Buffer is a diluent formulated to stabilize the activity of Chemicon horseradish peroxidase (HRP)-antibody conjugates at high conjugate dilution for extended periods....
... Camera hood with 5.6" TFT color screen, without ... system use digital camera with 8.0 mega pixel ... requirements and small budget. View image from large ... specific feature. It is suitable to capture image ...
...
Biology Products: